Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Elmer, Anne"" wg kryterium: Autor


Wyświetlanie 1-10 z 10
Tytuł :
Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease.
Autorzy :
Bergamaschi, Laura (AUTHOR)
Mescia, Federica (AUTHOR)
Turner, Lorinda (AUTHOR)
Hanson, Aimee L. (AUTHOR)
Kotagiri, Prasanti (AUTHOR)
Dunmore, Benjamin J. (AUTHOR)
Ruffieux, Hélène (AUTHOR)
De Sa, Aloka (AUTHOR)
Huhn, Oisín (AUTHOR)
Morgan, Michael D. (AUTHOR)
Gerber, Pehuén Pereyra (AUTHOR)
Wills, Mark R. (AUTHOR)
Baker, Stephen (AUTHOR)
Calero-Nieto, Fernando J. (AUTHOR)
Doffinger, Rainer (AUTHOR)
Dougan, Gordon (AUTHOR)
Elmer, Anne (AUTHOR)
Goodfellow, Ian G. (AUTHOR)
Gupta, Ravindra K. (AUTHOR)
Hosmillo, Myra (AUTHOR)
Pokaż więcej
Źródło :
Immunity (10747613). Jun2021, Vol. 54 Issue 6, p1257-1257. 1p.
Czasopismo naukowe
Tytuł :
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Autorzy :
Collier DA; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK.
De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Ferreira IATM; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.
Meng B; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.
Datir RP; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Kemp SA; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK.
Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Silacci-Fregni C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Bowen J; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Snell G; Vir Biotechnology, San Francisco, CA, USA.
Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Pellanda AF; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Riva A; Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy.
Elmer A; NIHR Cambridge Clinical Research Facility, Cambridge, UK.
Kingston N; NIHR Bioresource, Cambridge, UK.
Graves B; NIHR Bioresource, Cambridge, UK.
McCoy LE; Division of Infection and Immunity, University College London, London, UK.
Smith KGC; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.
Bradley JR; Department of Medicine, University of Cambridge, Cambridge, UK.; NIHR Bioresource, Cambridge, UK.
Temperton N; University of Kent, Canturbury, UK.
Ceron-Gutierrez L; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.
Barcenas-Morales G; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.; Laboratorio de Inmunologia, UNAM, Cuautitlán, Mexico.
Harvey W; Institute of Biodiversity, University of Glasgow, Glasgow, UK.
Virgin HW; Vir Biotechnology, San Francisco, CA, USA.
Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Doffinger R; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.
Wills M; Department of Medicine, University of Cambridge, Cambridge, UK.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. .; Department of Medicine, University of Cambridge, Cambridge, UK. .; Department of Haematology, University of Cambridge, Cambridge, UK. .; University of KwaZulu Natal, Durban, South Africa. .; Africa Health Research Institute, Durban, South Africa. .; Department of Infectious Diseases, Cambridge University Hospitals NHS Trust, Cambridge, UK. .
Pokaż więcej
Corporate Authors :
CITIID-NIHR BioResource COVID-19 Collaboration
COVID-19 Genomics UK (COG-UK) Consortium
Źródło :
Nature [Nature] 2021 May; Vol. 593 (7857), pp. 136-141. Date of Electronic Publication: 2021 Mar 11.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
COVID-19/*immunology
COVID-19/*therapy
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*immunology
Vaccines, Synthetic/*immunology
Aged ; Aged, 80 and over ; Angiotensin-Converting Enzyme 2/metabolism ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/isolation & purification ; Antibodies, Neutralizing/isolation & purification ; Antibodies, Viral/isolation & purification ; COVID-19/metabolism ; COVID-19/virology ; Female ; HEK293 Cells ; Humans ; Immune Evasion/genetics ; Immune Evasion/immunology ; Immunization, Passive ; Male ; Middle Aged ; Models, Molecular ; Mutation ; Neutralization Tests ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/metabolism ; Vaccines, Synthetic/administration & dosage
SCR Protocol :
COVID-19 serotherapy
Czasopismo naukowe
Tytuł :
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.
Autorzy :
Collier DA; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK.
De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Ferreira IATM; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.
Meng B; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.
Datir R; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Kemp S SA; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK.
Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Fregni CS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Bowen J; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Snell G; Vir Biotechnology, San Francisco, CA 94158, USA.
Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Pellanda AF; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
Riva A; Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy.
Elmer A; NIHR Cambridge Clinical Research Facility, Cambridge, UK.
Kingston N; NIHR Bioresource, Cambridge, UK.
Graves B; NIHR Bioresource, Cambridge, UK.
McCoy LE; Division of Infection and Immunity, University College London, London, UK.
Smith KG; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.
Bradley JR; Department of Medicine, University of Cambridge, Cambridge, UK.; NIHR Bioresource, Cambridge, UK.
Temperton N; University of Kent, Canturbury, UK.
Ceron-Gutierrez L L; Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK.
Barcenas-Morales G; Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK.; Laboratorio de Inmunologia, S-Cuautitlán, UNAM, Mexico.
Harvey W; Institute of Biodiversity, University of Glasgow, Glasgow, UK.
Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.
Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Doffinger R; Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK.
Wills M; Department of Medicine, University of Cambridge, Cambridge, UK.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; University of KwaZulu Natal, Durban, South Africa.; Africa Health Research Institute, Durban, South Africa.; Department of Infectious Diseases, Cambridge University Hospitals NHS Trust, Cambridge UK.
Pokaż więcej
Corporate Authors :
CITIID-NIHR BioResource COVID-19 Collaboration
COVID-19 Genomics UK (COG-UK) consortium
Źródło :
MedRxiv : the preprint server for health sciences [medRxiv] 2021 Feb 15. Date of Electronic Publication: 2021 Feb 15.
Typ publikacji :
Preprint
    Wyświetlanie 1-10 z 10

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies